GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market Challenges
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
yourlifechoices.com.au3h
Shingles vaccine access expanded
Access to the free shingles vaccine has been expanded to all immunocompromised people aged 18 and over. But experts fear that ...
GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
Medscape2d
Maternal Hepatitis C Virus Infection Linked to Increased NICU Admissions and SGA Births
The study highlighted that 57.7% of neonates in the case group had a diagnosis of neonatal abstinence syndrome compared to 10 ...
STAT5d
Millions of Americans want to quit smoking. Critics say drugmakers and the FDA are failing them
There hasn’t been a new class of drugs approved to help smokers quit since Pfizer's Chantix reached the market nearly two ...
Another Mistrial in Zantac: Fourth Illinois Jury Fails to Award Damages
On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...
LancasterOnline3d
GSK expansion project in East Donegal Township could get a tax break
East Donegal Township is considering a tax break that would benefit an expansion of the GSK vaccine packaging facility in ...
Critical Mass With Law.com's Amanda Bronstad: Johnson & Johnson Files Third Talc Bankruptcy, Zantac Mistrial Gives Plaintiffs Their Fourth Loss
In this month's trial, which began on Aug. 28, Eric Olson ( Olson Grimsley) and Ashley Keller ( Keller Postman) represented ...
Medscape9d
Best Survival Outcomes With Neoadjuvant Immunotherapy in Melanoma
Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...
Investing18d
GlaxoSmithKline hold rating reaffirmed by TD Cowen
TD Cowen maintained a Hold rating on GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), with a consistent price target of $1,790.00. The firm's stance comes after GlaxoSmithKline reported positive Phase ...